ELAN's Quality Score rose 1 point on Mon, Nov 2, to 8. It closed near its high of the day.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 4.5% today, while its drugmaker peers are down 1.7%; no story names it yet.
Lags the market
Down 30% over five years while the S&P 500 rose 76%.
The other side and the timeline, for Pro members.
| The company | Sales up 12% on the year |
| Latest filing | 10-Q, Aug 5 |
TodayNo story names it yet.
After its last 4 reports it closed +4.7% on average, higher 3 of 4 times.
Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
ELAN is #19 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 19 |
Net income over four quarters: ELAN -$199M, ZTS $2.62B.
Reports Fri Nov 6, before the open (in 4 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
ELAN's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $5.09B to $5.14B |
“Elanco expects adjusted gross margin of 55.2% to 55.6%, an increase of 50 basis points versus 2025 and compared to the prior expectation of 40 basis points of improvement.”
From its results filing (SEC filing · Aug 5)
Sales grew 7.6% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.4% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | +5.8% | +2.4% | -11.2% |
| May 6, 2026 | +1.1% | +13.9% | -6.8% |
| Feb 24, 2026 | -2.8% | +6.6% | +5.4% |
Sales grew in six of the last seven years, to $4.7B in 2025. It lost money in 2025 after a profit in 2024.
7 insiders bought $1.7M across 7 filings in the last 6 months. No open-market sales on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ELAN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
“We face intense competition globally.”
ELAN scores 8 today, which Breakaway calls Average. It is #19 of 92 in Pharma by Quality Score, with 5 of 14 chart checks firing. Down 30% over five years while the S&P 500 rose 76%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ELAN scores 8 today, which Breakaway calls Average (6 to 10). That is #19 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ELAN's 8.
7 insiders bought $1.7M across 7 filings in the last 6 months. No open-market sales on record. The newest is Lawrence Erik Kurzius, Director, who bought $936K on Aug 20. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.